UCB, a global biopharmaceutical company, has unveiled new research findings supporting its recently launched treatments in the generalized myasthenia gravis (gMG) portfolio. These findings will be presented at the 10th Congress of the European Academy of Neurology (EAN) from June…
Sure, here’s a rewritten version of the article: Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for their Omicron JN.1-adapted monovalent COVID-19 vaccine…
Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of their Omicron JN.1-adapted monovalent COVID-19 vaccine, COMIRNATY® JN.1, for active immunization against COVID-19 caused…
Roche’s PiaSky Receives Positive CHMP Opinion for PNH Treatment in EU Today, Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended PiaSky® (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). PiaSky,…
Roche announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for extending the marketing authorization of Vabysmo® (faricimab) to include the treatment of visual impairment due to macular edema…
Merck known as MSD outside the United States and Canada, announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has unanimously recommended CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years and…
Merck Announces Positive EU CHMP Recommendation for WINREVAIR™ (Sotatercept) in Treating Pulmonary Arterial Hypertension (PAH) Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of…
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has launched Allē Payment Plans, powered by Cherry, to offer consumers the ability to pay for aesthetic treatments and products, including BOTOX® Cosmetic (onabotulinumtoxinA) and the JUVÉDERM® Collection of Fillers, over time.…
AbbVie announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for inflammatory diseases. Celsius’ lead investigational asset, CEL383, is a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study…
TVM Capital Healthcare Announces $35 Million Investment in Boston Oncology Arabia TVM Capital Healthcare, an international healthcare expansion and growth capital firm, has announced a $35 million investment in Boston Oncology Arabia, a bio-generic drugs manufacturing company based in the…
Bristol Myers Squibb announced today that the European Medicines Agency (EMA) has validated its application to introduce a new subcutaneous administration route for Opdivo® (nivolumab). This includes a new pharmaceutical form (solution for injection) and a new strength (600 mg/vial)…
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer that harbors one or more PIK3CA, AKT1, or PTEN…